tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

KYMR Stock Latest News

Kymera Therapeutics Announces Positive Phase 1b Trial Results
Company AnnouncementsKymera Therapeutics Announces Positive Phase 1b Trial Results
7m ago
8K
KYMR
Kymera Therapeutics announces results from BroADen Phase 1b trial of KT-621
PremiumThe Fly
Kymera Therapeutics announces results from BroADen Phase 1b trial of KT-621
47m ago
KYMR
Kymera Therapeutics’ KT-621: Promising Potential in Atopic Dermatitis with Significant Upside
PremiumRatings
Kymera Therapeutics’ KT-621: Promising Potential in Atopic Dermatitis with Significant Upside
7d ago
KYMR
Kymera Therapeutics price target raised to $80 from $68 at Truist
PremiumThe Fly
Kymera Therapeutics price target raised to $80 from $68 at Truist
12d ago
KYMR
Kymera Therapeutics price target raised to $90 from $70 at UBS
PremiumThe Fly
Kymera Therapeutics price target raised to $90 from $70 at UBS
12d ago
KYMR
Kymera Therapeutics announces first patient dosed in BROADEN2 Phase 2b trial
PremiumThe FlyKymera Therapeutics announces first patient dosed in BROADEN2 Phase 2b trial
13d ago
KYMR
Kymera Therapeutics management to meet with Truist
Premium
The Fly
Kymera Therapeutics management to meet with Truist
1M ago
KYMR
Kymera Therapeutics price target raised to $84 from $70 at H.C. Wainwright
Premium
The Fly
Kymera Therapeutics price target raised to $84 from $70 at H.C. Wainwright
1M ago
KYMR
Kymera Therapeutics price target raised to $70 from $60 at Barclays
PremiumThe Fly
Kymera Therapeutics price target raised to $70 from $60 at Barclays
1M ago
KYMR
Kymera Therapeutics Reports Q3 2025 Financial Results
PremiumCompany Announcements
Kymera Therapeutics Reports Q3 2025 Financial Results
1M ago
KYMR
Kymera Therapeutics: Promising Developments and Strong Financial Position Justify Buy Rating
PremiumRatings
Kymera Therapeutics: Promising Developments and Strong Financial Position Justify Buy Rating
1M ago
KYMR
Kymera Therapeutics’ Earnings Call Highlights Growth and Challenges
PremiumCompany Announcements
Kymera Therapeutics’ Earnings Call Highlights Growth and Challenges
1M ago
KYMR
Kymera Therapeutics price target raised to $73 from $70 at Morgan Stanley
PremiumThe FlyKymera Therapeutics price target raised to $73 from $70 at Morgan Stanley
1M ago
KYMR
Positive Outlook for Kymera Therapeutics Driven by Promising STAT6 Degrader Developments and Upcoming Data Release
Premium
Ratings
Positive Outlook for Kymera Therapeutics Driven by Promising STAT6 Degrader Developments and Upcoming Data Release
1M ago
KYMR
Kymera Therapeutics price target raised to $73 from $64 at Jefferies
Premium
The Fly
Kymera Therapeutics price target raised to $73 from $64 at Jefferies
1M ago
KYMR
Kymera Therapeutics reports Q3 EPS (94c), consensus (79c)
PremiumThe Fly
Kymera Therapeutics reports Q3 EPS (94c), consensus (79c)
1M ago
KYMR
Kymera Therapeutics sees cash runway into 2H28
PremiumThe Fly
Kymera Therapeutics sees cash runway into 2H28
1M ago
KYMR
Kymera Therapeutics assumed with a Buy at Guggenheim
PremiumThe Fly
Kymera Therapeutics assumed with a Buy at Guggenheim
1M ago
KYMR
KYMR Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
KYMR Upcoming Earnings Report: What to Expect?
1M ago
KYMR
Kymera Therapeutics price target raised to $72 from $54 at BofA
PremiumThe FlyKymera Therapeutics price target raised to $72 from $54 at BofA
1M ago
KYMR
Kymera Therapeutics’ KT-579 Shows Promising Preclinical Results, Earning Buy Rating from Analyst
Premium
Ratings
Kymera Therapeutics’ KT-579 Shows Promising Preclinical Results, Earning Buy Rating from Analyst
1M ago
KYMR
Kymera Therapeutics Advances KT-621 Study for Atopic Dermatitis
Premium
Company Announcements
Kymera Therapeutics Advances KT-621 Study for Atopic Dermatitis
1M ago
KYMR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >